Longitudinal analysis of serum neutralization of SARS-CoV-2 Omicron BA.2, BA.4 and BA.5 in patients receiving monoclonal antibodies

Timothee BRUEL; Karl STEFIC; Yann NGUYEN; Donatella TONIUTTI; Isabelle STAROPOLI; Francoise PORROT; Florence GUIVEL-BENHASSINE; William Henry BOLLAND; Delphine PLANAS; Jerome HADJADJ; Lynda HANDALA; Cyril PLANCHAIS; Matthieu PROT; Etienne SIMON-LORIERE; Emmanuel ANDRE; Guy BAELE; Lize CUYPERS; Luc MOUTHON; Hugo MOUQUET; Julian BUCHRIESER; Aymeric SEVE; Thierry PRAZUCK; Piet MAES; Benjamin TERRIER; Laurent HOCQUELOUX; Olivier SCHWARTZ.
Preprint en Inglés | PREPRINT-MEDRXIV | ID: ppmedrxiv-22278699

Documentos relacionados

  1. Longitudinal analysis of serum neutralization of SARS-CoV-2 Omicron BA.2, BA.4, and BA.5 in patients receiving monoclonal antibodies.
  2. SARS-CoV-2 infection triggers more potent antibody-dependent cellular cytotoxicity (ADCC) responses than mRNA-, vector-, and inactivated virus-based COVID-19 vaccines.
  3. Serum neutralization of SARS-CoV-2 Omicron BA.2, BA.2.75, BA.2.76, BA.5, BF.7, BQ.1.1 and XBB.1.5 in individuals receiving Evusheld.
  4. Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies.
  5. SARS-CoV-2 Spike Stem Protein Nanoparticles Elicited Broad ADCC and Robust Neutralization against Variants in Mice.
  6. Resistance of Omicron subvariants BA.2.75.2, BA.4.6, and BQ.1.1 to neutralizing antibodies.
  7. Natural killer cell-mediated ADCC in SARS-CoV-2-infected individuals and vaccine recipients.
  8. Evaluating mAbs binding abilities to Omicron subvariant RBDs: implications for selecting effective mAb therapies.
  9. Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants.
  10. Targeted SARS-CoV-2 treatment is associated with decreased mortality in immunocompromised patients with COVID-19.